WE CLAIM:

1. A compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof.

2. The compound according to Claim 1 which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea.

3. The compound according to Claim 2 which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea in crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ ± 0.2, occurring at 16.0 and one or more of 6.9, 7.0, 18.2, and 23.2.

4. A pharmaceutical composition comprising a compound of Claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising the compound or salt according to any one of Claims 1-3, and a pharmaceutically acceptable carrier, diluent, or excipient.

6. A pharmaceutical composition comprising the compound or salt according to any one of Claims 1-3, and polyvinyl pyrrolidone vinyl acetate (PVP-VA).

7. The pharmaceutical composition according to Claim 6 wherein the PVP-VA is Kollidon® VA 64.

~~8. A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of the compound or salt according to any one of Claims 1-3.~~

~~9. The method according to Claim 8, wherein the cancer is selected from the group consisting of thyroid cancer, ovarian cancer, melanoma, acute myelogenous leukemia (AML), and colorectal cancer.~~

~~10. The method according to Claim 9, wherein the cancer is melanoma.~~

~~11. The method according to Claim 9, wherein the cancer is colorectal cancer.~~

8~~12~~. The compound or salt according to any one of Claims 1-3 for use in therapy.

9~~13~~. The compound or salt according to any one of Claims 1-3 for use in the treatment of cancer.

10~~14~~. The compound or salt for use according to Claim 9~~13~~, wherein the cancer is selected from the group consisting of thyroid cancer, ovarian cancer, melanoma, acute myelogenous leukemia (AML), and colorectal cancer.

11~~15~~. The compound or salt for use according to Claim 10~~14~~, wherein the cancer is melanoma.

12~~16~~. The compound or salt for use according to Claim 10~~14~~ wherein the cancer is colorectal cancer.